AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Rockwell Medical, Inc.
Video analysis: RMTI
All videosNo video analysis for this stock yet. Request one from our team.
News: RMTI
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.
Rockwell Medical Announces Second Quarter 2026 Results
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodial
Rockwell Medical Announces Second Quarter 2026 Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.
Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rockwell Medical Advances Quality and Regulatory Leadership
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical received notice from Nasdaq that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026.
Similar companies
-
Cumberland Pharmaceuticals Inc.
CPIX
·
NASDAQ
Compare
-
Quantum BioPharma Ltd.
QNTM
·
NASDAQ
Compare
-
Apimeds Pharmaceuticals US, Inc
APUS
·
New York Stock Exchange Arca
Compare
-
Liminatus Pharma, Inc. Class A Common Stock
LIMN
·
NASDAQ
Compare
-
Alterity Therapeutics Limited
ATHE
·
NASDAQ
Compare
-
Star Equity Holdings, Inc.
STRR
·
NASDAQ
Compare